What strategies are pharmaceutical companies using for global tigecycline patent term extension?

Why are companies pursuing patent term extensions for tigecycline?

Pharmaceutical companies pursue these extensions to offset time lost during regulatory review and clinical development. Regulators grant extensions only when a product faces delays beyond company control, such as lengthy FDA or EMA approval processes. For tigecycline, extensions have been sought because the drug reached market after significant development investment.

What alternatives to patent term extension exist for tigecycline coverage?

Some companies file additional patents on formulations, methods of use, or manufacturing processes. These secondary patents can add years of protection even when the base compound patent expires. Regulatory data exclusivity periods also provide market protection without needing an extension.

What happens when tigecycline patent extensions fail or are challenged?

When an extension request is rejected, companies lose exclusive rights sooner. History shows that generic manufacturers launch products once the main compound patent expires. Companies facing extension challenges often respond by asserting secondary patents in court to block generic entry.

How do regulatory timelines affect tigecycline patent extensions?

Regulatory delays during FDA and EMA reviews directly determine extension length. The amount of time a company receives equals the period between IND filing and NDA approval, minus half the clinical testing period, capped at five years total. The extension cannot push the patent term beyond 14 years from approval.

When does tigecycline exclusivity expire?

Exclusivity periods vary by region. In the United States, base compound protection ended in 2015. Secondary formulation patents and data exclusivity rules still provide coverage into the 2020s in several markets. In the EU, similar rules apply under supplementary protection certificates that compensate for review delays.

Who makes tigecycline and who competes with it?

Wyeth originally developed and patented tigecycline as Tygacil. Pfizer acquired Wyeth and holds most active patents. Generic versions now come from companies such as Teva, Sandoz, and other Indian manufacturers. Competition intensifies when primary protection ends and secondary patents fall under challenge.

Can biosimilars enter before tigecycline patent expiry?

Tigecycline is a small-molecule antibiotic, not a biological product. Biosimilars do not apply to it. Generic chemical copies enter once patents and data exclusivity expire.